Showing 711-720 of 23022 results for "".
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
https://reachmd.com/programs/cme/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerAdvancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
https://reachmd.com/programs/cme/advancing-gmg-clinical-decisions-diagnosing-early-treating-smarter-and-caring-holistically-a-case-based-treatment-approach/36276/Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment ApproachCDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
https://reachmd.com/programs/cme/cdh6-in-focus-advancing-biomarker-driven-strategies-for-platinum-resistant-ovarian-cancer/36229/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerMOA: CDH6-Targeted Antibody-Drug Conjugates
https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerEfficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Emerging Directions in Menin-Directed AML Therapy
https://reachmd.com/programs/cme/emerging-directions-in-menin-directed-aml-therapy/36184/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Ongoing Clinical Trials in AML With Menin Inhibitors
https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Managing Adverse Events Associated With Menin Inhibitors
https://reachmd.com/programs/cme/managing-adverse-events-associated-with-menin-inhibitors/36182/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.